Cataract

PARIS — Subgroup characteristics did not affect the clinical outcomes of SMILE Xtra, according to a study presented by Hyung-Jin Koo, MD, of Nunemiso Eye Center, Seoul, at the European Society of Cataract and Refractive Surgeons meeting.

PARIS — At the European Society of Cataract and Refractive Surgeons meeting, David Touboul, MD, PhD, speaks about a study currently ongoing in Bordeaux, France, in which OCT is used to measure crystalline lens position and diameter. A new method might be developed to optimize predictability of effective lens position and IOL selection.

PARIS — At the European Society of Cataract and Refractive Surgeons meeting, Francesco Carones, MD, speaks about his early results with the new Tecnis Synergy IOL (Johnson & Johnson Vision) for presbyopia. He also explains why this lens is able to provide unique advantages in terms of continuous, wide range of vision with no fluctuations from 30 cm to far distance, even in dim light conditions.

PARIS — Santen announced the European launch of its novel xact Mono-EDoF IOL at the European Society of Cataract and Refractive Surgeons meeting here.

PARIS — At the European Society of Cataract and Refractive Surgeons meeting, Noel Alpins, MD, gives pearls on how to prevent residual corneal astigmatism and related nighttime visual phenomena in LASIK patients. He also gives instructions on how to get access to an online free vector planning calculator.

PARIS — At the European Society of Cataract and Refractive Surgeons meeting, Tom Frinzi, worldwide president of surgical, Johnson & Johnson Vision, speaks about newly launched products: Tecnis Synergy, a continuous range of vision IOL for presbyopia, and two preloaded injectors, one disposable and one reusable. Commitment to innovation is the core philosophy of the company, he says.

The AcrySof IQ PanOptix trifocal IOL, the first trifocal lens for cataract surgery patients in the United States, has been approved by the FDA, Alcon announced in a press release.

AcuFocus has completed enrollment in a pivotal investigational device exemption study of the IC-8, its small aperture IOL for patients with cataracts, according to a press release.

No additional benefit in IOP-lowering effect was seen when goniosynechialysis was added to phacoemulsification in patients with primary angle closure glaucoma and cataract.

Hugh R. Taylor, AC, MD, participated in some of the earliest research associating cigarette smoking with eye disease while on the faculty at Johns Hopkins University. His epidemiological work continues in his current posts at the Centre for Eye Research Australia at the University of Melbourne.